{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T05:10:18Z","timestamp":1793855418613,"version":"4.6.1"},"reference-count":36,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR081151"],"award-info":[{"award-number":["R01AR081151"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.antiviral.2025.106151","type":"journal-article","created":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T04:17:56Z","timestamp":1743135476000},"page":"106151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tenofovir alafenamide promotes weight gain and impairs fatty acid metabolism-related signaling pathways in visceral fat tissue compared to tenofovir disoproxil fumarate"],"prefix":"10.1016","volume":"237","author":[{"given":"Bryan","family":"Dulion","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3921-8317","authenticated-orcid":false,"given":"Arnold Z.","family":"Olali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niyati","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amber K.","family":"Virdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0832-5646","authenticated-orcid":false,"given":"Ankur","family":"Naqib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennillee","family":"Wallace","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-234X","authenticated-orcid":false,"given":"Ryan D.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2025.106151_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. Roy. Stat. Soc. B"},{"key":"10.1016\/j.antiviral.2025.106151_bib2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jacc.2013.06.027","article-title":"Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality","volume":"62","author":"Britton","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.antiviral.2025.106151_bib3","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.1210\/clinem\/dgad411","article-title":"Weight gain after HIV therapy initiation: pathophysiology and implications","volume":"109","author":"Chandiwana","year":"2024","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.antiviral.2025.106151_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/bcpt.13161","article-title":"Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine","volume":"124","author":"Cid-Silva","year":"2019","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.antiviral.2025.106151_bib5","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s11904-018-0378-z","article-title":"HIV persistence in adipose tissue reservoirs","volume":"15","author":"Couturier","year":"2018","journal-title":"Curr. HIV AIDS Rep."},{"key":"10.1016\/j.antiviral.2025.106151_bib6","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.antiviral.2018.04.002","article-title":"Adipocytes impair efficacy of antiretroviral therapy","volume":"154","author":"Couturier","year":"2018","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2025.106151_bib7","first-page":"990","article-title":"Weight, anthropometric and metabolic changes after discontinuing antiretroviral therapy containing tenofovir alafenamide in people with HIV","volume":"79","author":"Damas","year":"2024","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2025.106151_bib8","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","article-title":"Weight gain and integrase inhibitors","volume":"33","author":"Eckard","year":"2020","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2025.106151_bib9","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/jac\/dkab158","article-title":"Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV","volume":"76","author":"Gonz\u00e1lez-Cord\u00f3n","year":"2021","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.antiviral.2025.106151_bib10","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2025.106151_bib11","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1038\/nrm2391","article-title":"Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes","volume":"9","author":"Guilherme","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.antiviral.2025.106151_bib12","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1038\/nrmicro2911","article-title":"Animal models for HIV\/AIDS research","volume":"10","author":"Hatziioannou","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.antiviral.2025.106151_bib13","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1093\/infdis\/jiac175","article-title":"Dolutegravir suppresses thermogenesis via disrupting uncoupling protein 1 expression and mitochondrial function in Brown\/beige adipocytes in preclinical models","volume":"226","author":"Jung","year":"2022","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.antiviral.2025.106151_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101412","article-title":"Evidence synthesis evaluating body weight gain among people treating HIV with antiretroviral therapy - a systematic literature review and network meta-analysis","volume":"48","author":"Kanters","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.antiviral.2025.106151_bib15","doi-asserted-by":"crossref","DOI":"10.1097\/QAD.0000000000002541","article-title":"Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV","volume":"34","author":"Lacey","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.antiviral.2025.106151_bib16","doi-asserted-by":"crossref","first-page":"4288","DOI":"10.1093\/nar\/gks042","article-title":"Differential expression analysis of multifactor RNA-Seq experiments with respect to biological variation","volume":"40","author":"McCarthy","year":"2012","journal-title":"Nucleic acids research"},{"key":"10.1016\/j.antiviral.2025.106151_bib17","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.stemcr.2014.12.005","article-title":"Nonirradiated NOD,B6.SCID Il2r\u03b3-\/- Kit(W41\/W41) (NBSGW) mice support multilineage engraftment of human hematopoietic cells","volume":"4","author":"McIntosh","year":"2015","journal-title":"Stem Cell Rep."},{"key":"10.1016\/j.antiviral.2025.106151_bib18","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.1210\/jc.2002-020635","article-title":"Differential regulation of adiponectin secretion from cultured human omental and subcutaneous adipocytes: effects of insulin and rosiglitazone","volume":"87","author":"Motoshima","year":"2002","journal-title":"The Journal of Clinical Endocrinology & Metabolism"},{"key":"10.1016\/j.antiviral.2025.106151_bib19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.antiviral.2025.106151_bib20","doi-asserted-by":"crossref","DOI":"10.3390\/cells11111841","article-title":"Inhibition of adipose tissue beiging by HIV integrase inhibitors, dolutegravir and bictegravir, is associated with adipocyte hypertrophy, hypoxia, elevated fibrosis, and insulin resistance in simian adipose tissue and human adipocytes","volume":"11","author":"Ngono Ayissi","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.antiviral.2025.106151_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/jbmrpl\/ziae037","article-title":"The anti-HIV drug abacavir stimulates \u03b2-catenin activity in osteoblast lineage cells","volume":"8","author":"Olali","year":"2024","journal-title":"JBMR Plus"},{"key":"10.1016\/j.antiviral.2025.106151_bib22","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/QAD.0000000000003455","article-title":"Adipocyte differentiation of 3T3-L1 cells under tenofovir alafenamide, tenofovir disoproxil fumarate, and integrase strand transfer inhibitors selective challenge: an in-vitro model","volume":"37","author":"Perna","year":"2023","journal-title":"Aids"},{"key":"10.1016\/j.antiviral.2025.106151_bib23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s00125-007-0841-7","article-title":"Fat depot-related differences in gene expression, adiponectin secretion, and insulin action and signalling in human adipocytes differentiated in vitro from precursor stromal cells","volume":"51","author":"Perrini","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.antiviral.2025.106151_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.116010","article-title":"Divergent effects of the antiretroviral drugs, dolutegravir, tenofovir alafenamide, and tenofovir disoproxil fumarate, on human adipocyte function","volume":"220","author":"Quesada-L\u00f3pez","year":"2024","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.antiviral.2025.106151_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2025.106151_bib26","first-page":"139","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2009","journal-title":"Bioinformatics (Oxford, England)"},{"key":"10.1016\/j.antiviral.2025.106151_bib27","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2025.106151_bib28","doi-asserted-by":"crossref","first-page":"S189","DOI":"10.1097\/QAD.0000000000003083","article-title":"Is tenofovir disoproxil fumarate associated with weight loss?","volume":"35","author":"Shah","year":"2021","journal-title":"Aids"},{"key":"10.1016\/j.antiviral.2025.106151_bib29","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1038\/s41366-022-01199-9","article-title":"20 Years with SGBS cells - a versatile in vitro model of human adipocyte biology","volume":"46","author":"Tews","year":"2022","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.antiviral.2025.106151_bib30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.antiviral.2025.106151_bib31","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.antiviral.2025.106151_bib32","doi-asserted-by":"crossref","DOI":"10.3390\/cells12071034","article-title":"An efficient humanized mouse model for oral anti-retroviral administration","volume":"12","author":"Virdi","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.antiviral.2025.106151_bib33","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.cell.2012.05.016","article-title":"Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human","volume":"150","author":"Wu","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.antiviral.2025.106151_bib34","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R Package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"OMICS A J. Integr. Biol."},{"key":"10.1016\/j.antiviral.2025.106151_bib35","article-title":"Tenofovir and adefovir down-regulate mitochondrial chaperone TRAP1 and succinate dehydrogenase subunit B to metabolically reprogram glucose metabolism and induce nephrotoxicity","volume":"7","author":"Zhao","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.antiviral.2025.106151_bib36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3389\/fcvm.2017.00027","article-title":"Humans and mice display opposing patterns of \"browning\" gene expression in visceral and subcutaneous white adipose tissue depots","volume":"4","author":"Zuriaga","year":"2017","journal-title":"Front. Cardiovasc. Med."}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354225000774?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0166354225000774?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,17]],"date-time":"2025-04-17T12:06:55Z","timestamp":1744891615000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0166354225000774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":36,"alternative-id":["S0166354225000774"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2025.106151","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tenofovir alafenamide promotes weight gain and impairs fatty acid metabolism-related signaling pathways in visceral fat tissue compared to tenofovir disoproxil fumarate","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2025.106151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106151"}}